Dr. Sartor on Outcomes With 177Lu-PSMA-617 After Radium-223 in mCRPC

A. Oliver Sartor, MD, a professor of medicine and medical director of the Tulane Cancer Center, and C. E. and Bernadine Laborde Professor of Cancer Research in the Department of Medicine and the Department of Urology at Tulane University, discusses the design of the REASSURE trial (NCT02141438) in patients with metastatic castration-resistant prostate cancer (mCRPC).

In the global, observational trial, investigators examined the long-term follow-up results of patients with mCRPC who received lutetium-177 PSMA-617 therapy after radium-223 dichloride (Xofigo), says Sartor. Graciously, investigators have a very extensive database that can be utilized to fully understand what the ultimate outcomes might be for this patient population, adds Sartor.

In addition to the information compiled on secondary cancers and survival rates, investigators also collected data with regard to various subsequent therapies, explains Sartor. To date, investigators are still trying to determine how effective these subsequent therapies were. However, factors such as the duration of time a patient received these therapies are being closely analyzed, adds Sartor.

Ultimately, the substrate of the study was to closely observe the outcomes of patients who were treated with radium-223 at selective practices as part of a prospective registry, and reporting on the subsequent use of 177Lu-PSMA therapy in these patients, concludes Sartor.